Reports Q3 revenue $1.46M, consensus $1.14M. “Securing agreement from the FDA to initiate a Phase 1 multiple dose administration trial is a key next step in our integrated development plan for Rhenium (186Re) Obisbemeda for patients with LM,” said Marc H. Hedrick, M.D., Plus Therapeutics (PSTV)’ President and Chief Executive Officer. “We are on track to complete both Phase 1 LM trials and move to later stage trials in 2025.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PSTV:
- Plus Therapeutics, SpectronRx announce manufacturing partnership
- PSTV Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Plus Therapeutics files $100M mixed securities shelf
- Biotech Alert: Searches spiking for these stocks today
- Plus Therapeutics’ Rhenium Obisbemeda shows safety, potential efficacy